Can analysts adopt a bullish outlook for Sanofi (NYSE:SNY)?

January 21, 2018 - By Marguerite Chambers

 Can analysts adopt a bullish outlook for Sanofi (NYSE:SNY)?

Sanofi (NYSE:SNY) Ratings Coverage

Among 12 analysts covering Sanofi-aventis Sa (NYSE:SNY), 1 have Buy rating, 1 Sell and 10 Hold. Therefore 8% are positive. Sanofi-aventis Sa had 23 analyst reports since October 15, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Friday, April 21 by JP Morgan. The firm has “Neutral” rating by Piper Jaffray given on Friday, September 23. The firm earned “Mkt Perform” rating on Monday, November 9 by Bernstein. Barclays Capital upgraded the shares of SNY in report on Thursday, May 12 to “Overweight” rating. The firm has “Underweight” rating by Morgan Stanley given on Friday, December 1. The firm earned “Underperform” rating on Thursday, December 10 by BNP Paribas. The company was upgraded on Thursday, September 8 by Berenberg. Argus Research initiated the shares of SNY in report on Thursday, April 6 with “Buy” rating. The firm has “Neutral” rating given on Wednesday, April 12 by JP Morgan. Cowen & Co maintained the shares of SNY in report on Friday, October 13 with “Hold” rating. Below is a list of Sanofi (NYSE:SNY) latest ratings and price target changes.

18/12/2017 Broker: Cowen & Co Rating: Hold New Target: $48.0 Maintain
06/12/2017 Broker: Bank of America Rating: Hold Downgrade
01/12/2017 Broker: Morgan Stanley Old Rating: Overweight New Rating: Underweight Downgrade
15/11/2017 Broker: Barclays Capital Old Rating: Underweight New Rating: Equal-Weight Upgrade
13/10/2017 Broker: Cowen & Co Rating: Hold New Target: $52.0 Maintain
05/09/2017 Broker: Cowen & Co Rating: Hold New Target: $52.0 Maintain
30/08/2017 Broker: HSBC Old Rating: Reduce New Rating: Hold Upgrade

The stock increased 0.20% or $0.09 during the last trading session, reaching $44.6. About 1.90M shares traded or 42.89% up from the average. Sanofi (NYSE:SNY) has risen 26.96% since January 21, 2017 and is uptrending. It has outperformed by 10.26% the S&P500.

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company has market cap of $106.91 billion. The firm operates in two divisions, Pharmaceuticals and Vaccines. It has a 10.18 P/E ratio. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

More notable recent Sanofi (NYSE:SNY) news were published by: Benzinga.com which released: “The Pullback In Sanofi Is A Buying Opportunity, Says Argus” on September 01, 2017, also Investorplace.com with their article: “5 Reasons Why Sanofi SA (ADR) (SNY) is a Good Stock to Buy Now” published on April 12, 2017, Benzinga.com published: “Regeneron And Sanofi Have A Near-Term FDA Catalyst” on May 22, 2017. More interesting news about Sanofi (NYSE:SNY) were released by: Investorplace.com and their article: “Think Sanofi SA (ADR) (SNY) Stock When You Think Big Pharma” published on December 09, 2016 as well as Investorplace.com‘s news article titled: “Sanofi SA (ADR): SNY Pipeline Is Overflowing With Potential” with publication date: April 14, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.